EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics

Tetiana Korzun iD, Abraham S Moses, Parham Diba iD, Ariana L Sattler, Olena R Taratula, Gaurav Sahay iD, Oleh Taratula iD, Daniel L Marks iD

Pharmaceuticals · 31.07.2023 · 16 (8) · 1088

DOI: 10.3390/ph16081088 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 31.07.2023. Verfasst von Tetiana Korzun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR 97201, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In biomedical applications, nanomaterial-based delivery vehicles, such as lipid nanoparticles, have emerged as promising instruments for improving the solubility, stability, and encapsulation of various payloads. This article provides a formal review focusing on the reactogenicity of empty lipid nanoparticles used as delivery vehicles, specifically emphasizing their application in mRNA-based therapies. Reactogenicity refers to the adverse immune responses triggered by xenobiotics, including administered lipid nanoparticles, which can lead to undesirable therapeutic outcomes. The key components of lipid nanoparticles, which include ionizable lipids and PEG-lipids, have been identified as significant contributors to their reactogenicity. Therefore, understanding the relationship between lipid nanoparticles, their structural constituents, cytokine production, and resultant reactogenic outcomes is essential to ensure the safe and effective application of lipid nanoparticles in mRNA-based therapies. Although efforts have been made to minimize these adverse reactions, further research and standardization are imperative. By closely monitoring cytokine profiles and assessing reactogenic manifestations through preclinical and clinical studies, researchers can gain valuable insights into the reactogenic effects of lipid nanoparticles and develop strategies to mitigate undesirable reactions. This comprehensive review underscores the importance of investigating lipid nanoparticle reactogenicity and its implications for the development of mRNA–lipid nanoparticle therapeutics in various applications beyond vaccine development.

Schlagwörter

Stichwörter der Autor:innen

empty lipid nanoparticlesionizable lipidsreactogenicityxenobiotics

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 S Moody Avenue, Portland, OR 97201, USA.
  • Department of Biomedical Engineering, Oregon Health & Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA.
  • Medical Scientist Training Program, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
  • Papé Family Pediatric Research Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
  • Knight Cancer Institute, Oregon Health & Science University, 2720 S Moody Avenue, Portland, OR 97201, USA.
  • Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, 2730 S Moody Avenue, Portland, OR 97201, USA.

ORCID-Profile: Tetiana Korzun, Parham Diba, Gaurav Sahay, Oleh Taratula, Daniel L Marks

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NEI NIH HHS
  • National Cancer Institute of the National Institutes of Health
  • OHSU Knight Cancer Institute
  • Friends of Doernbecher
  • College of Pharmacy at Oregon State University
  • Papé Family Pediatric Research Institute at Oregon Health & Science University

Zitieren

APA

Korzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023). From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics. Pharmaceuticals, 16(8), 1088. https://doi.org/10.3390/ph16081088

Vancouver

Korzun T, Moses AS, Diba P, Sattler AL, Taratula OR, Sahay G, et al. From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics. Pharmaceuticals. 2023;16(8):1088. doi:10.3390/ph16081088

BibTeX
@article{Korzun2023,
  author = {Korzun, Tetiana and Moses, Abraham S and Diba, Parham and Sattler, Ariana L and Taratula, Olena R and Sahay, Gaurav and Taratula, Oleh and Marks, Daniel L},
  title = {From Bench to Bedside: Implications of Lipid Nanoparticle Carrier Reactogenicity for Advancing Nucleic Acid Therapeutics},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {8},
  pages = {1088},
  doi = {10.3390/ph16081088}
}
Kostenlos starten →